8ZD.F ABBISKO CAYMAN DL-00001
- Market cap
- EUR 544M
- P/E
- -
- P/B
- 1.83x
- ROE
- 2.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 8ZD.F undervalued?
Graham numberThe Graham number of ABBISKO CAYMAN DL-00001 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ABBISKO CAYMAN DL-00001 fundamental analysis
No fundamental analysis for ABBISKO CAYMAN DL-00001 yet.
ABBISKO CAYMAN DL-00001 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ABBISKO CAYMAN DL-00001
Abbisko Medicine Co., Ltd., together with its subsidiaries, engages in the research, discovery, and development of pharmaceutical products in Mainland China and the European Union. The company develops Pimicotinib (ABSK021), a small molecule CSF-1R inhibitor, which is in NDA/commercial stage for the treatment of tenosynovial giant cell tumors and Phase Ib/II for the treatment of chronic graft versus host disease; and Irpagratinib (ABSK011), a small-molecule inhibitor of FGFR…
Full company profileABBISKO CAYMAN DL-00001 financial statements
ABBISKO CAYMAN DL-00001 annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 22.7M | 0.00 | 19.1M | 504M | 612M |
| Gross Profit | 22.7M | 0.00 | 19.1M | 504M | 612M |
| Operating Income | -314M | -487M | -490M | -8.40M | 42.7M |
| EBITDA | - | -477M | -411M | 103M | 142M |
| Net Income | -1.81B | -496M | -432M | 28.3M | 55.2M |
| EPS | -2.88 | -0.77 | -0.67 | 0.04 | 0.08 |
| Balance Sheet | |||||
| Total Assets | 2.65B | 2.49B | 2.12B | 2.11B | 2.35B |
| Total Liabilities | 118M | 143M | 134M | 149M | 430M |
| Shareholders' Equity | 2.54B | 2.35B | 1.98B | 1.96B | 1.92B |
| Cash & Short-term Investments | 2.55B | 642M | 578M | 290M | 749M |
| Cash Flow | |||||
| Operating Cash Flow | -170M | -344M | -445M | -12.9M | 79.3M |
| Capital Expenditure | 12.3M | 22.7M | 12.3M | 7.40M | 5.53M |
| Free Cash Flow | -182M | -367M | -457M | -20.3M | 73.8M |
| Ratios | |||||
| ROE | -71.4% | -21.1% | -21.8% | 1.4% | 2.9% |
| ROA | -68.2% | -19.9% | -20.4% | 1.3% | 2.3% |
| Net Profit Margin | -7,979.9% | - | -2,264.3% | 5.6% | 9.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
ABBISKO CAYMAN DL-00001 dividends
ABBISKO CAYMAN DL-00001 has not paid dividends in the last 5 fiscal years.
Who owns ABBISKO CAYMAN DL-00001
- Insiders 16.23%
- Institutions 37.56%
- Public & others 46.21%
- Shares outstanding 716M
- Free float 426M
ABBISKO CAYMAN DL-00001 company profile
- Company name
- ABBISKO CAYMAN DL-00001
- Ticker
- 8ZD.F
- ISIN
- KYG0028A1085
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 286
- Fiscal year end
- December
- Address
- Building 3, Shanghai, China
- Phone
- 86 21 6891 2098
- Website
- abbisko.com
About ABBISKO CAYMAN DL-00001
Abbisko Medicine Co., Ltd., together with its subsidiaries, engages in the research, discovery, and development of pharmaceutical products in Mainland China and the European Union. The company develops Pimicotinib (ABSK021), a small molecule CSF-1R inhibitor, which is in NDA/commercial stage for the treatment of tenosynovial giant cell tumors and Phase Ib/II for the treatment of chronic graft versus host disease; and Irpagratinib (ABSK011), a small-molecule inhibitor of FGFR4, which is in pivotal stage and Phase Ib/II for the treatment of hepatocellular carcinoma. It also engages in the development of ABSK061, which is in Phase Ib/II for the treatment of gastric cancer and achondroplasia; and ABSK043, which is in Phase Ib/II for the treatment of solid tumors and non-small cell lung cancer. In addition, the company develops drugs in Phase I/Ia clinical trial, including ABSK121 for solid tumors; ABSK112 for non-small cell lung and breast cancers; ABK3376 for non-small cell lung cancer; ABSK131 for solid tumors; ABSK141 for solid tumors; and ABSK051 for solid tumors, as well as ABSK012, which is in preclinical stage for the treatment of rhabdomyosarcoma and solid tumors. Further, it is involved in the development of drugs in IND enabling stage, such as P151 for cardiometabolic; and drugs in lead optimization stage comprising P011, P018, P020, and P017 for solid tumors, as well as P023 for obesity and P022 for atopic dermatitis, asthma, and chronic obstructive pulmonary disease. Additionally, the company provides advisory and management services. Abbisko Medicine Co., Ltd. was formerly known as Abbisko Cayman Limited and changed its name to Abbisko Medicine Co., Ltd. in September 2026. The company was founded in 2016 and is headquartered in Shanghai, China.
ABBISKO CAYMAN DL-00001 management
7- Dr. Yao-Chang XuFounder, Executive Chairman of the Board & CEO · born 1957
- Dr. Hongping YuCo-Founder, SVP of Chemistry, Chief Scientific Officer & Executive Director · born 1968
- Dr. Jing JiChief Medical Officer & Executive Director · born 1970
- Ms. Jia FengVP of HR and Operations & Head of Human Resource
- Dr. Zhen ZhangSenior VP of CMC & Head of Chemistry, Manufacturing and Controls · born 1973
- Ms. Sio Ngo LinJoint Company Secretary
- Ms. Hanxi ZhangJoint Company Secretary